340B Contract Pharmacy Management
The average covered entity contracts with around twenty pharmacy locations, and some with several hundred. Each one is an arrangement you are responsible for overseeing — and since 2020, more than thirty manufacturers have restricted access to some or all of them.
At a glance
- Avg. locations per entity
- ~20
- Manufacturers restricting
- 36+
- Common finding
- Oversight evidence
- Review output
- Location-level report
Where contract pharmacy exposure accumulates
Contract pharmacy arrangements let a covered entity extend 340B dispensing to retail and specialty pharmacies it does not own. They are legitimate, widely used, and — in most audits — the area with the highest concentration of findings.
The reason is structural. Oversight responsibility stays with the covered entity, but the data, the dispensing and the patient interaction all sit with a third party. Reconciliation runs through a TPA. Agreements were often signed years ago by people who have since left. And the manufacturer restriction landscape now changes several times a year.
Our review works location by location rather than in aggregate, because aggregate reporting is exactly what hides the problem.
Know the number before the letter arrives
Manufacturer restrictions on contract pharmacy access have expanded steadily since 2020. Some restrict all contract pharmacy, some allow a single designated location, some require claims data submission through a designated platform, and eligibility conditions differ by entity type. We model the impact against your actual drug mix and location footprint.
- Restriction inventory mapped to your specific drugs and locations
- Financial impact modeled against your actual purchase history
- Designated-pharmacy elections reviewed where a manufacturer permits one
- State law protections checked for every state you operate in
- Data submission requirements assessed for compliance and privacy implications
Contract pharmacy management services: common questions
How many contract pharmacies should we have?
As many as you can genuinely oversee and that produce meaningful patient access or capture. Entities regularly carry locations that generate almost no volume while consuming real oversight capacity. Our location-level review usually identifies several worth consolidating.
Are manufacturer restrictions legal?
That question is being actively litigated, and outcomes have differed across circuits. More than eighteen states have also enacted contract pharmacy protection laws, several of which are themselves under challenge. We track the position for the states you operate in and re-verify before advising, rather than working from a fixed list.
Who is responsible if a contract pharmacy makes an error?
The covered entity. Oversight responsibility cannot be delegated to the pharmacy or to the TPA, which is why documented oversight — not just contracted oversight — is what auditors look for.
Should we submit claims data to a manufacturer platform?
It is a decision with compliance, privacy and commercial dimensions, and it varies by manufacturer and by state. We assess what is actually being requested, what your state law says, and what the practical consequence of declining would be for your entity.
How many of your contract pharmacies were reviewed individually this year?
Aggregate reporting is where location-level problems go to hide.